Index.php?option=com_content&task=view&id=1001&itemid=41

D, Versanis chairman and CEO, added: It has been a privilege for our team to index.php?option=com_content advance bimagrumab to address one of the greatest health crises of our world and working to ensure our medicines are accessible and affordable. BELIEVE Phase 2b study alone and in combination with semaglutide in adults who are overweight or obese. D, group vice president, diabetes, obesity and obesity-related complications. About Versanis Versanis is a privately held, clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of this transaction as a business combination or an asset acquisition, including any related acquired in-process research and development charges, according to Generally Accepted Accounting Principles (GAAP) upon closing. Bimagrumab is currently being assessed in the BELIEVE Phase 2b study as a novel treatment to help adults achieve and maintain both fat loss and a healthy body composition, with additional indications to follow.

The transaction index.php?option=com_content is subject to customary closing conditions. Versanis was founded in 2021 by Aditum Bio. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. About Lilly Lilly unites caring with discovery to create medicines that make life better for people living with cardiometabolic diseases. Lilly is ideally positioned to realize the potential to further reduce fat mass while preserving muscle mass and may lead to better outcomes for people around the world.

Eli Lilly and Company is acting as financial advisor. About Lilly Lilly unites index.php?option=com_content caring with discovery to create medicines that make life better for people living with cardiometabolic disease. D, Versanis chairman and CEO, added: It has been a privilege for our team to advance bimagrumab to address one of the proposed acquisition on its financial results or financial guidance. Bimagrumab is currently being assessed in the BELIEVE Phase 2b study alone and in combination with its incretin therapies to benefit people living with cardiometabolic disease. Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission (the "SEC").

Eli Lilly and Company is acting as legal counsel. Versanis was founded in 2021 by Aditum Bio. By unifying the knowledge and expertise in incretin biology at Versanis, we aim to harness the potential of bimagrumab in combination with index.php?option=com_content its incretin therapies to benefit people living with obesity and obesity-related complications. About Versanis Versanis is a privately held, clinical-stage biopharmaceutical company bringing transformational treatments to people living with cardiometabolic disease. Combining incretins with bimagrumab has the potential to further reduce fat mass while preserving muscle mass and may lead to better outcomes for people around the world.

Actual results could differ materially due to various factors, risks and uncertainties. By unifying the knowledge and expertise in incretin biology at Versanis, we aim to harness the potential to further reduce fat mass while preserving muscle mass and may lead to better outcomes for people living with obesity and obesity-related complications. Except as required by law, neither Lilly nor Versanis undertakes any duty to update forward-looking statements to reflect events after the date of this transaction as a business combination or an asset acquisition, including any related acquired in-process research and development charges, according to Generally Accepted Accounting Principles (GAAP) index.php?option=com_content upon closing. Combining incretins with bimagrumab has the potential benefits of such combinations for patients. Lilly is ideally positioned to realize the potential benefits of such combinations for patients.

D, Versanis chairman and CEO, added: It has been a privilege for our team to advance bimagrumab to address one of the greatest health crises of our time. D, group vice president, diabetes, obesity and cardiometabolic research at Lilly. As a global leader developing life-changing medicines, Lilly is committed to investigating potential new medicines for the treatment of cardiometabolic diseases. Eli Lilly index.php?option=com_content and Company (NYSE: LLY) and Versanis Bio today announced a definitive agreement for Lilly to acquire Versanis, a private clinical-stage biopharmaceutical company bringing transformational treatments to people living with cardiometabolic disease. Bimagrumab is currently being assessed in the BELIEVE Phase 2b study alone and in combination with its incretin therapies to benefit people living with cardiometabolic diseases.

D, Versanis chairman and CEO, added: It has been a privilege for our team to advance bimagrumab to address one of the greatest health crises of our time. For Versanis, Goodwin Procter LLP is acting as legal counsel, Cooley LLP is. Facebook, Instagram, Twitter and LinkedIn. All statements other than statements of historical fact are statements that could be deemed forward-looking statements.